Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

Vivani Medical, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COMPANY PLANS RAPID ADVANCEMENT OF SEMAGLUTIDE IMPLANT NPM-139, FOLLOWING POSITIVE WEIGHT LOSS DATA FROM AN ONGOING PRECLINICAL STUDY OF NPM-139 AND PROMISING RESULTS FROM THE LIBERATE-1 PHASE 1 CLINICAL STUDY OF NPM-115

VIVANI MEDICAL PROVIDES BUSINESS UPDATE INCLUDING $10M EQUITY FINANCING AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

ALL SUBJECTS IN THE NPM-115 COHORT HAD SUCCESSFUL INSERTIONS OF A MINIATURE, ULTRA LONG-ACTING GLP-1 (EXENATIDE) IMPLANT IN THE ON-GOING LIBERATE-1 STUDY IN OBESE OR OVERWEIGHT INDIVIDUALS; TOP-LINE RESULTS ARE ANTICIPATED IN MID-2025

VIVANI MEDICAL PROVIDES BUSINESS UPDATE INCLUDING $3M EQUITY FINANCING AND REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

ALAMEDA, CALIF., MAY 07, 2025 (GLOBE NEWSWIRE) -- VIVANI MEDICAL, INC. (NASDAQ: VANI) (THE COMPANY OR VIVANI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MINIATURE, ULTRA LONG-ACTING DRUG IMPLANTS, ANNOUNCED TODAY THAT CEO ADAM MENDELSOHN, PH.D., WILL PRESENT AND PARTICIPATE IN A PANEL DISCUSSION AT THE AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS' (AAPS) BEYOND GLP1S: WHERE THE SCIENCE WILL TAKE BUSINESS NEXT VIRTUAL WORKSHOP, TAKING PLACE FROM MAY 13-14, 2025.

VIVANI MEDICAL TO PRESENT AT THE AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS' BEYOND GLP1S: WHERE THE SCIENCE WILL TAKE BUSINESS NEXT VIRTUAL WORKSHOP

OVER HALF OF ALL DOGS IN THE UNITED STATES TODAY ARE OVERWEIGHT OR OBESE, PLACING THEM AT INCREASED RISK FOR CHRONIC DISEASES, METABOLIC DECLINE AND SHORTENED LIFESPANS OVER HALF OF ALL DOGS IN THE UNITED STATES TODAY ARE OVERWEIGHT OR OBESE, PLACING THEM AT INCREASED RISK FOR CHRONIC DISEASES, METABOLIC DECLINE AND SHORTENED LIFESPANS

VIVANI MEDICAL AND OKAVA EXPAND COLLABORATION TO DEVELOP OKV-119 FOR DOGS, TARGETING METABOLIC HEALTH AND LONGEVITY

SUCCESSFUL INITIAL ADMINISTRATION AND FULL ENROLLMENT IN FIRST-IN-HUMAN LIBERATE-1  STUDY OF NPM-115 (EXENATIDE IMPLANT) IN OBESE AND OVERWEIGHT SUBJECTS WITH TOP-LINE DATA EXPECTED IN MID-2025

VIVANI MEDICAL PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

FINANCING STRENGTHENS BALANCE SHEET, EXTENDING EXPECTED RUNWAY INTO THE SECOND QUARTER OF 2026 ENABLES ACCELERATED DEVELOPMENT OF NPM-139, COMPANY'S ONCE OR TWICE-YEARLY GLP-1 (SEMAGLUTIDE) IMPLANT UNDER DEVELOPMENT FOR CHRONIC WEIGHT MANAGEMENT ALAMEDA, CALIF., MARCH 27, 2025 (GLOBE NEWSWIRE) -- VIVANI MEDICAL, INC. (NASDAQ: VANI) (VIVANI OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MINIATURE, ULTRA LONG-ACTING DRUG IMPLANTS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT TO ISSUE AND SELL AN AGGREGATE OF 7,366,071 SHARES, EACH AT A PRICE OF $1.12 PER SHARE, EXPECTED TO RESULT IN GROSS PROCEEDS OF APPROXIMATELY $8.25 MILLION IN A PRIVATE PLACEMENT.

VIVANI MEDICAL ANNOUNCES $8.25M PRIVATE PLACEMENT EQUITY FINANCING

NANOPORTAL TECHNOLOGY SUCCESSFULLY DELIVERS SEMAGLUTIDE, THE ACTIVE INGREDIENT IN OZEMPIC/WEGOVY, IN A PRECLINICAL STUDY WITH NPM-139 (SEMAGLUTIDE IMPLANT)

VIVANI MEDICAL ANNOUNCES POSITIVE PRECLINICAL WEIGHT LOSS DATA FOR NPM-139 SEMAGLUTIDE IMPLANT, WITH POTENTIAL FOR ONCE-YEARLY DOSING

ALAMEDA, CALIF.--(BUSINESS WIRE)--VIVANI MEDICAL, INC. (NASDAQ: VANI) (VIVANI OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MINIATURE, ULTRA LONG-ACTING DRUG IMPLANTS, ANNOUNCED TODAY THAT IT WILL PRESENT AT THE EMERGING GROWTH CONFERENCE ON MARCH 27, 2025. VIVANI WELCOMES INDIVIDUAL AND INSTITUTIONAL INVESTORS, ALONG WITH ADVISORS AND ANALYSTS, TO JOIN ITS INTERACTIVE PRESENTATION. THIS LIVE ONLINE EVENT WILL OFFER EXISTING SHAREHOLDERS AND THE INVESTMENT COMMUNITY.

VIVANI MEDICAL TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON MARCH 27, 2025

ALAMEDA, CALIF.--(BUSINESS WIRE)--VIVANI MEDICAL, INC. (NASDAQ: VANI) (VIVANI OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MINIATURE, ULTRA LONG-ACTING DRUG IMPLANTS, TODAY ANNOUNCED THE SUCCESSFUL ADMINISTRATION OF ITS FIRST GLP-1 (EXENATIDE) IMPLANT IN THE LIBERATE-1 CLINICAL TRIAL. THIS MILESTONE MARKS A CRITICAL STEP TOWARD ADDRESSING ONE OF HEALTHCARE'S MOST PRESSING CHALLENGES: MEDICATION ADHERENCE IN METABOLIC DISEASES INCLUDING CHRONIC WEIGHT MANAGEMENT AN.

VIVANI MEDICAL ACHIEVES FIRST IMPLANT AND FULL ENROLLMENT IN THE FIRST-IN-HUMAN CLINICAL TRIAL OF GLP-1 IMPLANT NPM-115 IN OBESE OR OVERWEIGHT ADULTS

ALAMEDA, CALIF.--(BUSINESS WIRE)--VIVANI MEDICAL, INC. (NASDAQ: VANI) (VIVANI OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MINIATURE, ULTRA LONG-ACTING DRUG IMPLANTS, TODAY ANNOUNCED THAT IT INTENDS TO SPIN OFF CORTIGENT, INC., A DIVISION THAT DEVELOPS BRAIN IMPLANT DEVICES TO HELP PEOPLE RECOVER CRITICAL BODY FUNCTIONS, AS AN INDEPENDENT PUBLICLY-TRADED COMPANY. THE STRATEGIC GOAL OF THIS TRANSACTION IS TO CREATE TWO FOCUSED COMPANIES DEDICATED TO DRIVING CURRENT.

VIVANI MEDICAL ANNOUNCES INTENT TO SPIN OFF CORTIGENT NEUROSTIMULATION BUSINESS

ALAMEDA, CALIF.--(BUSINESS WIRE)--VIVANI MEDICAL, INC. (NASDAQ: VANI) (VIVANI OR THE COMPANY), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ULTRA LONG-ACTING DRUG IMPLANTS, TODAY ANNOUNCED THAT SCREENING AND ENROLLMENT OF THE FIRST-IN-HUMAN CLINICAL TRIAL, KNOWN AS LIBERATE-1, HAS BEEN INITIATED AT TWO CENTERS IN AUSTRALIA TO INVESTIGATE THE SAFETY, TOLERABILITY AND FULL PHARMACOKINETIC PROFILE OF AN EXENATIDE IMPLANT. THIS STUDY IS THE FIRST CLINICAL APPLICATION OF THE COMPAN.

Vivani Medical, Inc.

VANI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Vivani Medical, Inc.

VANI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VANI